SecBot SecBot

EXEL drug pipeline

EXELIXIS, INC. · 3 rated drugs
$69.00
−1.2% 1-day · Nov 13
Next catalyst
Mar 3, 2027
zanzalintinib PDUFA date · in 107 days
Typical move on FDA news
±4.8%
1-day, median of 4 events
IV rank
46
IV 42% · HV 30%
Rated drugs
3
2 mixed · 1 neutral
Phase 3 trials
1
0 with results posted

Upcoming catalysts

2 dated
  1. Dec 15, 2026
    zanzalintinib
    Phase 3 primary completion
  2. Mar 3, 2027107d
    zanzalintinib
    PDUFA date · metastatic CRC

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseNDA filed / Under FDA Review (PDUFA Dec 3, 2026); Phase 3 completed (STELLAR-303); Phase 3 ongoing (STELLAR-311 NET); Ph
Time to marketIf approved, potential launch in late 2026 or early 2027 (PDUFA decision December 3, 2026); other indications (neuroendocrine tumors, NSCLC, prostate cancer) are in earlier-stage trials, likely years away.

zanzalintinib Updated Jun 30

107days
Next catalyst
PDUFA date · Mar 3, 2027 · metastatic CRC
What to watch

Watch the PDUFA date (December 3, 2026) closely as the key binary. The STELLAR-303 split results (ITT positive, NLM subgroup negative) complicate FDA approval odds but analysts suggest approval is still possible given the positive ITT data. Monitor for an FDA Advisory Committee date and any additional communications from the FDA. Elevated short interest (~55-60% short ratio) suggests the market is skeptical, creating potential for a squeeze on positive news, but equally large downside if the FDA issues a CRL.

Bull case
  • Zanzalintinib demonstrated a statistically significant 20% reduction in risk of death (HR 0.80; P=0.0045) in the full ITT population of STELLAR-303, making it the first immunotherapy-based regimen to show an OS benefit in MSS/MSI-low metastatic CRC (source: ir.exelixis.com press release Oct 2025).
  • The FDA accepted the NDA with a PDUFA date of December 3, 2026, and at least two groups of analysts suggested approval is still on the table despite the split results, noting the positive ITT data provides a strong efficacy signal (source: Fierce Biotech June 2026).
  • Exelixis has a massive pipeline expansion path beyond CRC, ongoing STELLAR-311 Phase 3 in neuroendocrine tumors, plus planned Phase 3 trials in squamous NSCLC and mCRPC in H2 2026, offering multiple shots on goal (source: intellectia.ai earnings summary May 2026).
Bear case
  • The final analysis of STELLAR-303 failed its dual primary endpoint, OS in patients without liver metastases was not statistically significant (HR 0.83; 95% CI 0.66-1.05; P=0.1185), which Fierce Biotech characterized as a clinical 'failure' and creates material FDA approval risk (source: biospace.com press release June 22, 2026; Fierce Biotech June 22, 2026).
  • Truist Securities downgraded EXEL from Buy to Hold on June 25, 2026 following the disappointing STELLAR-303 final analysis, and the consensus analyst price target of $49.50 sits below the current ~$54 stock price, suggesting limited near-term upside.
  • Multiple insiders sold shares in May-June 2026, including R&D head Dana Aftab (43,451 shares at $50.35), CFO Patrick Haley (32,110 shares), and directors George Poste (60,000 shares), a coordinated wave of selling ahead of the negative data readout.
◆ mixed
Impact
PhasePhase 3 (NDA under FDA review)
Time to marketThe FDA PDUFA target action date for the zanzalintinib + atezolizumab combination is March 3, 2027. If approved, a commercial launch would follow shortly after.

Tecentriq atezolizumab Updated Oct 30

What to watch

The next hard catalyst is the FDA PDUFA decision on the zanzalintinib + atezolizumab (Tecentriq) combination for previously treated metastatic CRC, now set for March 3, 2027 after a 3-month extension. An approval would give Exelixis a second commercial franchise beyond Cabometyx; a CRL or further delay would pressure the stock given the mixed STELLAR-303 data (ITT OS hit, NLM subgroup miss) and the safety signal of 5 treatment-related deaths in the combo arm.

Bull case
  • STELLAR-303 is the first Phase 3 trial to show a statistically significant overall survival improvement with an immunotherapy-based regimen in non-MSI-H / MSS metastatic colorectal cancer, a historically immunotherapy-resistant population.
  • The ITT population met its OS primary endpoint with a hazard ratio of 0.80 (p=0.0045), and median OS was 10.9 months vs 9.4 months for regorafenib.
  • If approved, the zanzalintinib + atezolizumab combination would be a chemotherapy-free oral + immunotherapy option for heavily pretreated CRC patients with no good alternatives.
Bear case
  • STELLAR-303 missed its second dual primary endpoint: OS in patients without liver metastases was not statistically significant (HR 0.83, p=0.1185), raising questions about the breadth of the benefit.
  • The FDA extended the PDUFA by 3 months to March 3, 2027 after Exelixis submitted updated safety and efficacy data classified as a major amendment, signaling potential review concerns.
  • There were 5 treatment-related deaths in the zanzalintinib + atezolizumab arm versus 1 in the regorafenib arm in STELLAR-303, a safety imbalance the FDA may scrutinize.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed since 2012 (first approval for medullary thyroid cancer)

cabozantinib Updated Jul 14

What to watch

Cabozantinib is Exelixis's sole approved drug, generating ~$2.12B in 2025 U.S. net revenue (17% YoY growth). The stock's next catalyst is the zanzalintinib PDUFA (Dec 3, 2026), not cabozantinib. For Kura Oncology holders: Kura's darlifarnib+cabozantinib combo data (44% ORR in pretreated ccRCC) is about Kura's drug resensitizing tumors to cabozantinib, not about cabozantinib itself. Watch Exelixis for cabozantinib commercial trends and the zanzalintinib readout.

Bull case
  • Cabozantinib franchise generated ~$2.12B in U.S. net product revenue in 2025 (+17% YoY), with 2026 guidance of $2.325B–$2.425B, indicating continued commercial growth (source: Exelixis Q4/FY2025 earnings, ir.exelixis.com)
  • Nine consecutive years of profitability with ~$1.66B cash position and $750M stock buyback authorization, zero dilution risk for shareholders (source: biotechdistilled.substack.com analysis, Jan 2026)
  • New indication approvals in differentiated thyroid cancer and neuroendocrine tumors (March 2025) are expanding the addressable market (source: FDA.gov approval announcement)
Bear case
  • Exelixis remains a single-product company economically anchored to cabozantinib, if sales erode due to competition or patent expiry, there is no other approved drug to cushion the impact (source: Wikipedia and FiercePharma Jan 2026 analysis)
  • Competitive pressure is intensifying in RCC and HCC from PD-1/CTLA-4 combos, HIF-2α inhibitors, and next-gen TKIs that could erode cabozantinib's market share over time (source: Strategic Market Research, kidney cancer drugs market report)
  • No pending binary catalyst for cabozantinib itself in the next 12 months, the next major catalyst for EXEL is zanzalintinib's PDUFA (Dec 3, 2026), a separate drug with its own binary risk (source: Exelixis Q1 2026 earnings press release)

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Feb 1, 2026zanzalintinibNDA filed+3.5%+6.1%
Mar 1, 2025cabozantinibApproval−0.4%−0.3%
Apr 25, 2016cabozantinibApproval+6.1%+9.3%
Nov 29, 2012cabozantinibApproval−7.6%−18.0%

Clinical trials

5 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
zanzalintinibStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaPhase 3Active not recruiting317Dec 15, 2026
cabozantinibA Phase II Trial of Cabozantinib With Patients With Refractory GCTsPhase 2Completed50Jul 31, 2026
cabozantinibCabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Phase 2Terminated · results4May 12, 2025
cabozantinibPh II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaPhase 2Completed · results34Nov 25, 2023
cabozantinibMultiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapsePhase 2Terminated · results19May 2011